Urgent Alert: DEA Proposes Temporary Federal Ban on 7-Hydroxymitragynine (7-OH), Threatening Kratom Product Sales

The United States Drug Enforcement Agency (DEA) has published a notice in the Federal Register indicating its intent to temporarily place 7-hydroxymitragynine (7-OH) on Schedule I of the Controlled Substances Act. This emergency rule could temporarily classify covered 7-OH products as Schedule I for up to two years while the DEA considers permanent scheduling. The earliest a temporary Schedule I ban could take effect is August 5, 2026, following a public comment period that concludes on July 31.

This action, if implemented, would impose regulatory controls and administrative, civil, and criminal sanctions on individuals and businesses that handle (manufacture, distribute, import, export, possess, etc.) 7-hydroxymitragynine above a specified threshold. The DEA's decision is based on an assessment of three factors from 21 U.S.C. § 811(c), concluding that concentrated 7-OH products pose an "imminent hazard to the public safety."

Specifically, the DEA cites:

• History and Current Pattern of Abuse: Rapid emergence of 7-OH products marketed for psychoactive, opioid-like effects.
• Scope, Duration, and Significance of Abuse: Quick expansion of availability and use across the United States, with increasing reports of misuse.
• Risk to Public Health: Reports of poison center calls, emergency department visits, overdoses, adverse events, dependence, and withdrawal, supported by scientific evidence from animal studies indicating 7-OH is a potent mu-opioid receptor agonist.

The Department of Health and Human Services (HHS) is accepting public comments on this notice through July 31, 2026.

The 'So What?' for Merchants:

• Immediate legal status changes: The DEA intends to temporarily place 7-hydroxymitragynine (7-OH) on Schedule I of the Controlled Substances Act. If enacted, this federal prohibition would make the manufacture, distribution, and possession of 7-OH above a specified threshold illegal, potentially effective as early as August 5, 2026, following a public comment period ending July 31.
• Payment processing/bank stability risks: A federal Schedule I classification for 7-OH would almost certainly trigger heightened scrutiny from payment processors, banks, and financial institutions. Merchants selling products containing 7-OH could face immediate account freezes, termination of services, or significantly increased compliance burdens and processing fees.
• Shipping/logistics warnings: Once 7-OH is federally scheduled, major shipping carriers (e.g., USPS, FedEx, UPS) would likely cease transporting products containing the substance. This poses a significant risk of shipment seizures, delays, and potential legal penalties for merchants attempting to ship such products.

Source: Kratom Science via Sentinel Newsroom